100% Quality Guarantee
PhD-Level Technical Support
Immunocytochemistry/Immunofluorescence analysis using Mouse Anti-Cav3.2 Monoclonal Antibody, Clone N55/10 (STMA00082). Tissue: Neuroblastoma cells (SH-SY5Y). Species: Human. Fixation: 4% PFA for 15 min. Primary Antibody: Mouse Anti-Cav3.2 Monoclonal Antibody (STMA00082) at 1:50 for overnight at 4°C with slow rocking. Secondary Antibody: AlexaFluor 488 at 1:1000 for 1 hour at RT.
Key Features

Anti-Cav3.2 Antibody [N55/10 (Formerly sold as S55-10)]

SKU STMA00082
Antibody Type Monoclonal
Applications WB
Applications IHC
Applications ICC/IF
Applications IP
Applications AM
Reactivity Human
Reactivity Mouse
Reactivity Rat
Host Species Mouse
Isotype IgG1
$854

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

Cav3.2 Antibody [N55/10 (Formerly sold as S55-10)]

Cav3.2 Antibody [N55/10 (Formerly sold as S55-10)] is a mouse monoclonal antibody directed against Cav3.2, offered by Assay Genie for research applications. Reported applications include WB, IHC, ICC/IF, IP and AM. Reported reactivity: Human, Mouse and Rat. Supplied as IgG1, purified by Protein G.

Cav3.2, encoded by the CACNA1H gene, is a low-voltage-activated T-type calcium channel that plays a critical role in regulating neuronal excitability, rhythmic firing, and calcium homeostasis. It is widely expressed in the brain and peripheral tissues, where it contributes to burst firing in thalamic neurons and modulates sensory signal transmission. Genetic studies have linked mutations in CACNA1H to childhood absence epilepsy, highlighting Cav3.2’s role in thalamocortical oscillations and seizure susceptibility. Beyond epilepsy, dysregulation of Cav3.2 expression and function has been associated with broader neurological and neurodegenerative conditions, including neuropathic pain, Parkinson’s disease, and Alzheimer’s disease. Its involvement in calcium dysregulation—a hallmark of neurodegeneration—positions Cav3.2 as a potential therapeutic target for modulating neuronal survival and excitability. Interestingly, Cav3.2 is also implicated in non-neuronal pathologies, such as prostate cancer progression, where its upregulation may support androgen-independent tumor growth. This underscores the channel’s broader physiological relevance and potential as a drug target across multiple disease domains. Despite its clinical significance, many aspects of Cav3.2’s in vivo function, regulatory mechanisms, and disease-specific roles remain under investigation. Advancing our understanding of Cav3.2 could open new avenues for targeted therapies in epilepsy, neurodegeneration, and beyond. This antibody is also available conjugated to ATTO 390, ATTO 488, ATTO 594, APC, Biotin, FITC, HRP, PerCP and RPE. Supplied in 100 µg. For research use only; not for diagnostic or therapeutic procedures.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose